Literature DB >> 3484634

Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28.

R Foa, M T Fierro, P Lusso, D Raspadori, M L Ferrando, L Matera, F Malavasi, F Lauria.   

Abstract

The proportion of E-rosette positive T-lymphocytes capable of reacting with three monoclonal antibodies (MoAbs)--Leu-11, A10, AB8.28--which appear to recognize specifically natural killer (NK) cells, was assessed in a series of untreated patients with B-cell chronic lymphocytic leukaemia (B-CLL). Irrespective of the clinical stage of the disease, the capacity of B-CLL T-lymphocytes to react with all three MoAbs was significantly reduced compared with that of normal circulating T-cells (Leu-11: 2.5% +/- 1.9 SD; A10: 2.3% +/- 1.3; AB8.28: 7% +/- 6.6 v Leu-11: 13.5% +/- 4.5; A10: 8.5% +/- 4.6; AB8.28: 12% +/- 5.5). Furthermore, a marked difference was demonstrated between the reactivity with the Leu-11, A10, AB8.28 MoAbs and the proportion of Leu-7 positive T-cells, which in B-CLL is significantly higher than in normal blood (23% +/- 12.1 v 11.9% +/- 5.9). These findings are in agreement with previous evidence of a discrepancy in B-CLL between the phenotypic expression, assessed by Leu-7 positivity, and the true functional activity of NK T-cells, and suggest that the Leu-11, A10 and AB8.28 MoAbs correlate well with the depressed NK function found in this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484634     DOI: 10.1111/j.1365-2141.1986.tb02911.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Cytotoxic lymphocytes in B-cell chronic lymphocytic leukemia. A flow cytometric study of peripheral blood, lymph nodes and bone marrow.

Authors:  L W Terstappen; B G de Grooth; I Segers-Nolten; J Greve
Journal:  Blut       Date:  1990-02

3.  Identification of protamine 1 as a novel cancer-testis antigen in early chronic lymphocytic leukaemia.

Authors:  Farouk Meklat; Yana Zhang; Masum Shahriar; Sharif U Ahmed; Wei Li; Nikolaos Voukkalis; Zhiqing Wang; Jian Zhang; Suhkrob Mastulov; Andrew Jewell; Thomas Giannakouros; Seah H Lim
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

4.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma.

Authors:  T Wen; H Mellstedt; M Jondal
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

Review 6.  Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Authors:  Silvia Sánchez-Ramón; Fatima Dhalla; Helen Chapel
Journal:  Front Immunol       Date:  2016-08-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.